Ask Sterling

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving the EV sector growth?

Madrigal Pharmaceuticals

Compare Madrigal Pharmaceuticals…

Rezdiffra (resmetirom): first FDA-approved MASH treatment (March 2024, thyroid hormone receptor-beta agonist). Q1 2026 net sales $311M (+127% YoY), 42,250+ patients on therapy. Competes with GLP-1 in MASH.

$MDGLWest Conshohocken, PA290Biotechnologymadrigalpharma.com

SectorsGLP-1

Mega Chart

All metrics are vertically resized to show how they've changed over time. They're not on the same Y-axis. This chart is meant to compare trends, not values.

3 metrics selected

Stock Price

Income Statement

Balance Sheet

Short-term Investments

Short-term Debt

Long-term Debt

Total Debt

Accounts Receivable

Inventory

Accounts Payable

Cash Flow

Operating Cash Flow

Free Cash Flow

Capital Expenditures

Per Share

Dividend Per Share

Margins

R&D % of Revenue

SG&A % of Revenue

Returns

Return on Equity

Return on Assets

Asset Turnover

Growth

Net Income Growth YoY

EPS Growth YoY

Ratios

Current Ratio

Quick Ratio

Debt-to-Equity

Debt-to-Assets

Interest Coverage

Efficiency

Days Sales Outstanding

Days Inventory Outstanding

Days Payable Outstanding

Macro

Values normalized to 0-100 scale for comparison. Hover for actual values.